GSK
GSK
787 hedge funds and large institutions have $11B invested in GSK in 2018 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 260 increasing their positions, 294 reducing their positions, and 54 closing their positions.
41% more call options, than puts
Call options by funds: $123M | Put options by funds: $87.4M
13% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 54
7% more funds holding in top 10
Funds holding in top 10: 14 → 15 (+1)
0% more funds holding
Funds holding: 787 → 787 (0)
0.01% less ownership
Funds ownership: 4.43% → 4.42% (-0.01%)
1% less capital invested
Capital invested by funds: $11.1B → $11B (-$60.7M)
12% less repeat investments, than reductions
Existing positions increased: 260 | Existing positions reduced: 294
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$218M |
| 2 |
Renaissance Technologies
New York
|
+$32.8M |
| 3 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$29.5M |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$25.7M |
| 5 |
Morgan Stanley
New York
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$154M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$71.6M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$40.1M |
| 4 |
Millennium Management
New York
|
-$30.7M |
| 5 |
CIM
Confluence Investment Management
St. Louis,
Missouri
|
-$22.2M |
GSK Hedge Fund Activity: Q3 2018 in Review
787 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2018, worth a combined $11B — down 0.55% from $11.1B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new GSK positions and 54 closed out — a net gain of 7 holders — while 260 added to existing stakes and 294 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $218M. The largest seller was Bank of New York Mellon, cutting an estimated $154M.
- 787 institutional investors held GSK (GSK) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $11B of GSK stock for Q3 2018, down 0.55% quarter-over-quarter.
- 61 funds opened new GSK positions in Q3 2018 and 54 closed out, a net change of +7 holders.
- The largest GSK buyer in Q3 2018 was Arrowstreet Capital, an estimated $218M added.
- The largest GSK seller in Q3 2018 was Bank of New York Mellon, an estimated $154M sold.
Based on aggregated 13F filings for Q3 2018.